α-Methylacyl Coenzyme A Racemase Is Immunoreactive in Extramammary Paget Disease

Daniel Mayes; James Patterson; Dharam Ramnani; Stacey Mills
April 2007
American Journal of Clinical Pathology;Apr2007, Vol. 127 Issue 4, p567
Academic Journal
α-Methylacyl-coenzyme A racemase (AMACR) has become a common tool in the diagnosis of morphologically difficult prostatic carcinoma and often is used in combination with the basal cell markers p63 and 34βE12. Outside this context, applications have been limited. Although initially considered a specific marker of prostatic carcinoma, immunoreactivity for AMACR has been found in a variety of other neoplasms. We report findings in 21 cases of extramammary Paget disease (EMPD), a neoplasm not previously reported to show AMACR immunoreactivity. We found immunoreactivity for AMACR in 15 (71%) of 21 EMPD cases overall, in 5 (56%) of 9 cases in women, and in 10 (83%) of 12 cases in men. AMACR immunoreactivity is a common finding in EMPD in men and women.


Related Articles

  • Criteria for tumor marker evaluation and utilization. Fleisher, Martin // MLO: Medical Laboratory Observer;Apr2003, Vol. 35 Issue 4, p16 

    Describes the requirements that tumor marker assays should exhibit for screening, diagnosing and monitoring cancer. Definition of a tumor marker; Evaluation of the efficacy of tumor markers; Comparison of sensitivity to specificity; Clinical uses of tumor markers; Pre-analytical considerations;...

  • Using tumor markers in cancer screening and follow-up.  // Patient Care;3/30/1999, Vol. 33 Issue 6, p109 

    Evaluates the clinical significance of tumor markers in cancer screening and follow-up. Tumor-associated markers; Genetic markers as tools in identifying neoplasms; Elements of a good neoplastic assessment.

  • S&T researcher develops technique to detect breast cancer in urine.  // Medical Device Daily;5/31/2013, Vol. 17 Issue 105, Special section p2 

    The article reports that Missouri Institute of Science and Technology chemistry professor Yinfa Ma discovered the use of P-scan for screening breast cancer in human urine. The device identified metabolites called pteredines in urine samples, as they can depict signs of cancer. The concept was...

  • MOLECULAR EXPRESSION OF BREAST TUMOUR MARKERS IN THE MNU MODEL FOLLOWING BFGF AND PF4 INTERVENTION. Norasikin, M. N.; Hasnan, J. // Malaysian Journal of Medical Sciences;Jan2007 Supplement, Vol. 14, p93 

    Introduction: Angiogenesis plays an important role in breast cancer development. Rapid tumour growth is dependent on angiogenesis to support the metabolic need of the fast-growing transformed tumour cells and the growth of the tumour beyond a certain size requires angiogenesis. While many...

  • Another clue to foil a wily enemy: Measuring protein tumor markers outside the primary tissue in breast carcinoma. Tawfik, Ossama // MLO: Medical Laboratory Observer;Jan2013, Vol. 45 Issue 1, p8 

    The article focuses on the plausible role of the Ki-67 protein expression as a biomarker for determining the growth fraction of a tumor. It discusses a study investigating the prognostic significance of evaluating the Ki-67 expression in axillary lymph node metastases as compared to primary...

  • Tumour biomarkers: diagnostic, prognostic, and predictive.  // BMJ: British Medical Journal;8/8/2015, Vol. 351 Issue 8020, ph3449 

    The article presents questions and answers related to tumor biomarkers in a breast cancer patient whose cancer metastasized to the brain .

  • Chemotherapy: Updates and New Perspectives. SWAIN, SANDRA M. // Oncologist;Dec2010 Supplement, Vol. 15, p8 

    Treatment options for patients with breast cancer have progressively improved over the past 40 years, from an era of no chemotherapy to the introduction of taxanes, hormonal therapy, and biologic therapy. These advances have resulted in substantial, 15%-20% improvements in clinical outcomes....

  • Where and by Whom Should Gastric Cancer HER2/neu Status Be Assessed? Lessons From Breast Cancer. Salto-Tellez, Manuel; Yau, Ee Xuan; Yan, Benedict; Fox, Stephen B. // Archives of Pathology & Laboratory Medicine;Jun2011, Vol. 135 Issue 6, p693 

    The author discusses the oncology treatment and HER2/neu in context of gastric cancer. Several studies conducted to test HER2/neu for relevance in gastric cancer are discussed. The author states it is necessary to establish general guidelines and technology having sufficient volume and...

  • Combining prostate markers may yield useful screening tool. Nelson, Nancy J. // JNCI: Journal of the National Cancer Institute;9/6/95, Vol. 87 Issue 17, p1281 

    Reports on the discovery of the gene known as kang ai (KAI1) which may be useful in a screening approach that combines several prostate cancer markers. Potential of E-cadherin as a tool for prostate cancer diagnosis; Insufficiency of prostate-specific antigen (PSA) blood test as a predictor of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics